Mark Emberton holds the post of Reader in interventional oncology at the University College London and is an Associate Professor at Middlesex University, London, UK. AT UCLH, he is the Clinical Director of Cancer Services. He is also the Clinical Director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England. His clinical and research interests are focused mainly on diseases of the prostate gland, both benign and malignant. In prostate cancer, much of his activity is at present focused on evaluating minimally invasive therapies for localised prostate cancer. This work encompasses the fields of precise characterisation of disease as well as targeting therapies. He is also interested in the methodological aspects of clinical research, particularly on the use of alternatives to the randomised control trial in surgery. He is involved in guideline production and appraisal and is interested in the formulation of evidence-based management policies. He is an active researcher, has lectured widely, and has published over 150 peer-reviewed articles in numerous scientific journals.
Biography Updated on 4 February 2010